CXJ2080 是一种选择性基于 PROTAC 的 CDK7 降解剂,DC50 值为 0.88 nM,它招募 VHL E3 连接酶,诱导依赖泛素-蛋白酶体途径的 CDK7 降解,破坏 CDK7-cyclin H-MAT1 复合物,抑制 CDK7 依赖的 RNA 聚合酶 II CTD Ser5、CDK1 Thr161 及 CDK2 Thr160 磷酸化,激活 p53-p21 轴,抑制 MYC 驱动的信号通路,诱导白血病细胞周期阻滞、凋亡 (apoptosis) 和分化,降低 CD117 表达,对血小板和正常 PBMC 无损伤,在洗脱后可维持 CDK7 持续降解,可用于急性白血病的研究(粉色:CDK7 配体 (MS-O10378);蓝色:VHL 配体 (MS-R24210);黑色:连接子)。
CXJ2080
产品编号: MS-Q16669 分子式: C51H68ClN11O6S2 分子量: 1030.74
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

CXJ2080 是一种选择性基于 PROTAC 的 CDK7 降解剂,DC50 值为 0.88 nM,它招募 VHL E3 连接酶,诱导依赖泛素-蛋白酶体途径的 CDK7 降解,破坏 CDK7-cyclin H-MAT1 复合物,抑制 CDK7 依赖的 RNA 聚合酶 II CTD Ser5、CDK1 Thr161 及 CDK2 Thr160 磷酸化,激活 p53-p21 轴,抑制 MYC 驱动的信号通路,诱导白血病细胞周期阻滞、凋亡 (apoptosis) 和分化,降低 CD117 表达,对血小板和正常 PBMC 无损伤,在洗脱后可维持 CDK7 持续降解,可用于急性白血病的研究(粉色:CDK7 配体 (MS-O10378);蓝色:VHL 配体 (MS-R24210);黑色:连接子)。

生物实验数据

生物活性 CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 value of 0.88 nM that recruits VHL E3 ligase to induce ubiquitin-proteasome pathway-dependent CDK7 degradation, disrupt the CDK7-cyclin H-MAT1 complex, and inhibit CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160; it activates the p53-p21 axis, suppresses MYC-driven signaling pathways, induces cell cycle arrest, apoptosis, and differentiation in leukemia cells, reduces CD117 expression, causes no damage to platelets and normal PBMCs, sustains CDK7 degradation after washout, and can be used for acute leukemia research (pink: CDK7 ligand (MS-O10378); blue: VHL ligand (MS-R24210); black: linker).
IC50 & Target

CDK7

 

体外研究
(In Vitro)

CXJ2080 (0.5-200 nM;6 小时) 可强效降解 MV4-11 急性髓系白血病细胞中的 CDK7,其 DC50 为 0.88 nM,最大降解效率>98%。
CXJ2080 (72 小时) 可强效抑制 RS4;11 急性淋巴细胞白血病细胞 (IC50 = 17.29 nM) 和 MV4-11 急性髓系白血病细胞的增殖 (IC50 = 4.31 nM)。
CXJ2080 (72 小时) 可抑制原代急性髓系白血病患者来源细胞样本的增殖。
CXJ2080 (100 nM;4 小时预处理) 可在 MV4-11 急性髓系白血病细胞中诱导 CDK7 持续降解,且洗脱后抑制作用可维持 48 h。
CXJ2080 (5-100 nM;8 小时) 可在 MV4-11 急性髓系白血病细胞中诱导剂量依赖性的 CDK7 降解、p53 积累、Myc 下调以及 p21 蛋白的双相应答。
CXJ2080 (5-100 nM;12 小时) 可在 MV4-11 急性髓系白血病细胞中诱导剂量依赖性细胞周期阻滞,且在较高浓度下会增加 SubG1 期细胞的累积。
CXJ2080 (5-100 nM;48 小时) 可在 MV4-11 急性髓系白血病细胞中诱导剂量依赖性凋亡。
CXJ2080 (5-100 nM;24 小时) 可显著降低 MV4-11 急性髓系白血病细胞中 CD117 (c-KIT) 干性标志物的表达。

Western Blot Analysis

Cell Line: MV4-11 acute myeloid leukemia cells
Concentration: 100 nM
Incubation Time: 4 h
Result: Maintained CDK7 degradation for 48 h post-washout.

Western Blot Analysis

Cell Line: MV4-11 acute myeloid leukemia cells
Concentration: 5 nM; 20 nM; 100 nM
Incubation Time: 8 h
Result: Degraded CDK7 in a dose-dependent manner.
Induced accumulation of p53 protein.
Downregulated Myc protein.
Caused a biphasic response in p21 protein levels (upregulated at low concentrations, downregulated at high concentrations).

Cell Cycle Analysis

Cell Line: MV4-11 acute myeloid leukemia cells
Concentration: 5 nM; 20 nM; 100 nM
Incubation Time: 12 h
Result: Induced cell cycle arrest in a dose-dependent manner.
Increased accumulation of cells in the SubG1 phase at higher concentrations.

Apoptosis Analysis

Cell Line: MV4-11 acute myeloid leukemia cells
Concentration: 5 nM; 20 nM; 100 nM
Incubation Time: 48 h
Result: Induced apoptosis in a dose-dependent manner.
Showed a higher proportion of apoptotic cells observed at higher concentrations.
Exhibited more potent apoptotic effects than TZ1104.
体内研究
(In Vivo)

CXJ2080 (20-50 mg/kg;静脉注射;隔日一次;2 周) 以 50 mg/kg 隔日一次静脉注射给药时,可在 RS4;11 异种移植肿瘤中实现强效肿瘤生长抑制及选择性 CDK7 降解,同时对 PBMCs 无损伤。
CXJ2080 (20-50 mg/kg;静脉注射;每隔 1 天;3 周) 以 50 mg/kg 的剂量每隔 1 天静脉注射给药时,可在 MV4-11 异种移植肿瘤中实现强效的肿瘤生长抑制,并选择性降解 CDK7,同时不损伤外周血单个核细胞 (PBMCs) 且维持正常的血小板参数。
CXJ2080 (20 mg/kg;静脉注射;隔日一次;共 21 天) 以 20 mg/kg 的剂量隔日静脉注射给药,可显著提高播散性 Molm13 急性髓系白血病小鼠的存活率。

Animal Model: Nu/Nu (female; 6-8 weeks old; implanted subcutaneously in
the right flank with 5 × 106 RS4;11 cells for a RS4;11 subcutaneous xenograft model)
Dosage: 20 mg/kg; 50 mg/kg
Administration: i.v.; every other day; 2 weeks
Result: Resulted in tumor weights similar to vehicle controls at 20 mg/kg.
Significantly reduced tumor weights relative to vehicle controls at 50 mg/kg.
Achieved robust CDK7 degradation in tumor tissues at 50 mg/kg.
Caused no significant reduction in CDK7 levels in PBMCs at 50 mg/kg.
Animal Model: Nu/Nu (female; 6-8 weeks old; implanted subcutaneously in
the right flank with 5 × 106 MV4-11cells for a MV4-11 subcutaneous xenograft model)
Dosage: 20 mg/kg; 50 mg/kg
Administration: i.v.; every other day; 3 weeks
Result: Resulted in tumor weights similar to vehicle controls at 20 mg/kg.
Significantly reduced tumor weights relative to vehicle controls at 50 mg/kg.
Achieved robust CDK7 degradation in tumor tissues at 50 mg/kg.
Caused no significant reduction in CDK7 levels in PBMCs at 50 mg/kg.
Maintained stable platelet counts, platelet-large cell ratio (P-LCR), and plateletcrit (PCT) throughout the treatment period at 50 mg/kg.
Animal Model: NOD scid gamma (NSG) (female; 6-8 weeks old; inoculated intravenously with 2 × 104
Molm13 cells via the tail vein for a Molm13 disseminated xenograft model)
Dosage: 20 mg/kg
Administration: i.v.; every other day; 21 days
Result: Significantly extended the survival of Molm13 tumor-bearing mice relative to vehicle controls.
Maintained a low leukemia burden in spleens of two surviving mice at the experimental endpoint.

化学信息

分子量 1030.74
分子式 C51H68ClN11O6S2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础